Figure 5
SR9243 induces immune-mediated TNBC tumor destruction in vivo. (A,B) E0771-tumor volumes in C57BL6J mice treated with vehicle (DMSO:Tween80:PBS/10:10:80) or 60 mg/kg SR9243 for 16 days. A: Line graph showing growth of individual tumors. B: Line graph showing the mean tumor volume for each group. (C,D) EMT6-tumor volumes in C57BL6J mice treated with vehicle or 60 mg/kg SR9243. C: Line graph showing growth of individual tumors. (D) Line graph showing the mean tumor volume for each group. (E,F) E0771-tumor volumes in Foxn1nu nude mice treated with vehicle or 60 mg/kg SR9243. C: Line graph showing growth of individual tumors. (D) Line graph showing the mean tumor volume for each group. Mice were implanted with 1 × 106 E0771 or 2 × 105 EMT6 cells in the lower left mammary fat pad. Tumors were allowed to establish to 50 mm3 then mice were treated with 60 mg/kg SR9243 or vehicle (10:10:80-DMSO:Tween80:PBS) once daily for 16 days (n = 6). Tumor volume was calculated using perpendicular caliper measurements (1/2LW2). *p < 0.05 as determined by 2-Way-ANOVA (G) Histogram displaying the number of tumor resident dendritic cells (CD11C + MHCII+) in SR9243 versus vehicle treated E0771 tumor-bearing C57BL6J mice quantified by FACs. (H) Average percentage of tumor resident DCs (CD11c + MHCII+) in tumors (I) FACs dot-plot showing the percentages of tumor resident myeloid derived suppressor cells (MDSCs: PMN-MDSCs: CD11B + Ly6G + Ly6C−) and monocytic MDSCs (M-MDSCs: CD11b + Ly6G-Ly6C+) resident in E0771-tumors implanted in C57BL6J mice. (J) Average percentage of tumor resident PMN-MDSCs and M-MDSCs (right panel) in control versus SR9243 groups determined by FACs (n = 6). (K) FACs-dot plot showing the percentage of tumor-resident CD8+ T-cells in response to SR9243 treatment. (L) Average percentage of CD8+ T-cells among tumor infiltrating lymphocytes in vehicle and SR9243 treated tumors.
